MSFP
KPTI icon

Mark Sheptoff Financial Planning’s Karyopharm Therapeutics KPTI Stock Holding History

Mark Sheptoff Financial Planning’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-53
Closed -$14K – 346
2018
Q3 		$14K Hold
53
– – 0.01% 267
2018
Q2 		$14K Buy
+53
New +$13.1K 0.01% 251

Other funds holding KPTI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCI
Ridgeback Capital Investments Miami Beach, Florida $560K AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Mark Sheptoff Financial Planning's KPTI Position: Q4 2018 in Review

Mark Sheptoff Financial Planning sold out of Karyopharm Therapeutics (KPTI) in Q4 2018, closing a stake of 53 shares — an estimated $14K sold.

Mark Sheptoff Financial Planning first reported a position in KPTI in Q2 2018 and held it in 2 quarters. The position peaked at $14K in Q3 2018. 115 funds tracked by Wall St. Rank hold KPTI as of Q4 2018.

  • Mark Sheptoff Financial Planning reported no remaining Karyopharm Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Mark Sheptoff Financial Planning sold 53 Karyopharm Therapeutics shares in Q4 2018, an estimated $14K.
  • Mark Sheptoff Financial Planning first reported a position in Karyopharm Therapeutics in Q2 2018 and held it in 2 quarters.
  • Mark Sheptoff Financial Planning's Karyopharm Therapeutics position peaked at $14K in Q3 2018.
  • 115 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2018.

Based on Mark Sheptoff Financial Planning's 13F filing for Q4 2018, filed 11 Feb 2019.